



Nebraska Department of Health and Human Services
HEALTH ALERT NETWORK
Advisory



TO: Primary care providers, infectious disease, laboratories, infection control, and public health

FROM Thomas J. Safranek, M.D. Jeff Hamik
State Epidemiologist Vector-borne Disease Epidemiologist
402-471-2937 PHONE 402-471-1374 PHONE
402-471-3601 FAX 402-471-3601 FAX

RE: LYME DISEASE IN NEBRASKA

DATE: April 23, 2019

The arrival of spring marks the beginning of another tick season. In the interest of public health and prevention, our office seeks to inform Nebraska health care providers about Lyme disease, including proper testing of suspect cases and treatment.


Key messages for Nebraska clinicians:

Lyme Disease

Lyme disease is transmitted by the tick *Ixodes scapularis* which is currently not thought to be established in Nebraska. **This fact makes any diagnosis of Nebraska-acquired Lyme disease caused by *Borrelia burgdorferi* highly suspect.** Lyme disease is highly regional in the United States with most cases reported from the Northeast and upper Midwest. In 2018, Nebraska reported 13 cases to the national reportable disease system at the CDC. All cases where exposure could be determined had exposure/acquisition in regions of the country where this tick is endemic. However, Nebraska is on the periphery of the known range of the tick vector and it appears to be continuing to expand further west and north out of this range. **Therefore, providers suspecting Lyme disease must be vigilant and take care to order the correct serologic tests in the proper order.**

Serologic testing for Lyme disease is currently the best method for lab diagnosis. It **requires a strict two-step process.** The first required test is either an enzyme immunoassay (EIA) or immunofluorescence assay (IFA). If this test yields negative results, the provider should consider an alternative diagnosis. Or in cases where the patient has had symptoms for less than or equal to 30 days, the provider may treat the patient and follow up with a convalescent serum. If the first test yields positive or equivocal results, two options are available: 1) if the patient has had symptoms for less than or equal to 30 days, an IgM and IgG Western blot is performed; 2) if the patient has had symptoms for more than 30 days, the IgG Western blot is performed. **The IgM should not be used if the patient has been ill for more than 30 days.** Positive serologic evidence **requires both the EIA (or IFA) and Western blot to be positive.** This testing algorithm optimizes sensitivity and specificity in untreated patients (<https://www.cdc.gov/lyme/healthcare/index.html>).

Two-Tiered Testing for Lyme Disease



National Center for Emerging and Zoonotic Infectious Diseases
Division of Vector Borne Diseases | Bacterial Diseases Branch



Understanding the EIA Test

Several types of EIA tests exist. Validated and FDA-approved EIAs include “ELISA” (enzyme-linked immunosorbent assay) and “ELFA” (enzyme-linked fluorescent immunoassay). Lyme disease testing measures a person’s antibody to the bacteria that cause Lyme disease. EIA tests are designed to be ultra “sensitive”, meaning that when they are used properly, almost everyone with Lyme disease will test positive. It is also possible, however, to test positive with an EIA test even when you do not have Lyme disease. This can occur because of other medical conditions, including but not limited to:

- Tick-borne relapsing fever
- Syphilis
- Anaplasmosis (formerly known as granulocytic ehrlichiosis)
- Leptospirosis
- Some autoimmune disorders (e.g., lupus)
- Bacterial endocarditis
- Infection with *Helicobacter pylori*, Epstein Barr virus, or *Treponema denticola* (bacteria found in the mouth that can cause gum disease and/or infection after dental procedures)

For this reason, providers should verify any “positive” or “equivocal” (indeterminate) EIA results by performing an immunoblot test such as a Western blot. The Western blot or other FDA-approved type of immunoblot can help distinguish patients who have Lyme disease from those with other conditions.

Understanding the Immunoblot Test

The immunoblot is a laboratory test that looks for antibodies the body makes against different molecules, or “antigens,” that are part of the *Borrelia burgdorferi* bacteria. Western blots were the first type of immunoblot developed for Lyme disease testing. Later, a striped type of immunoblot was approved by the FDA that does not require human interpretation of bands. Practically speaking, the test produces something that looks like a bar code used on grocery items, with several lines or “bands”. Each line represents antibodies to a different component of the bacteria. As with bar codes, the presence of any one or two lines is not particularly meaningful. Instead, it is the combination of multiple, specific lines that identifies the infection as being due to *Borrelia burgdorferi*.

Immunoblot tests for Lyme disease testing can detect two different classes of antibodies: IgM and IgG. IgM antibodies are made sooner, so testing for them can be helpful for identifying patients during the first few weeks of infection. The downside of testing for IgM antibodies is that they are **more likely to give false positive results**. Tests for IgG antibodies are more reliable, but can take 4-6 weeks for the body to produce in large enough quantities for the test to detect them. This process is complicated and often difficult to understand. Just remember the following:

- The immunoblot **should not** be run without first performing an EIA or IFA.
- The immunoblot **should not** be run if the EIA or IFA tests are negative.
- A positive IgM immunoblot is only meaningful during the first 4 weeks of illness
- If you’ve been ill for longer than 4-6 weeks and the IgG immunoblot test is negative, it is unlikely that you have Lyme disease, even if the IgM immunoblot is positive.

Note on test result interpretation: It is not correct to interpret a test result that has only some bands that are positive as being “mildly” or “somewhat” positive for Lyme disease. The criterion that requires at least 5 IgG bands reflects the fact that people with Lyme disease have at least 5 antigens (specific molecules) detectable.

Laboratory Tests that are Not Recommended

Some laboratories offer Lyme disease testing using assays whose accuracy and clinical usefulness have not been adequately established. Examples of unvalidated tests include:

- Capture assays for antigens in urine
- Culture, immunofluorescence staining, or cell sorting of cell wall-deficient or cystic forms of *B. burgdorferi*
- Lymphocyte transformation tests
- Quantitative CD57 lymphocyte assays
- “Reverse Western Blots”
- In-house criteria for interpretation of immunoblots
- Measurements of antibodies in joint fluid (synovial fluid)
- IgM or IgG Western Blot tests without a previous ELISA/EIA/IFA

Treatment

Per CDC guidance:

- People treated with appropriate antibiotics in the early stages of Lyme disease usually recover rapidly and completely. Antibiotics commonly used for oral treatment include doxycycline, amoxicillin, or cefuroxime axetil. People with certain neurological or cardiac forms of illness may require intravenous treatment with antibiotics such as ceftriaxone or penicillin.

- Treatment regimens listed in Table 1 are for localized (early) Lyme disease. For treatment of patients with disseminated (late) Lyme disease, please see references by Hu 2016 and Sanchez 2016. These regimens are guidelines only and may need to be adjusted depending on a person’s age, medical history, underlying health conditions, pregnancy status, or allergies.
- For people intolerant of amoxicillin, doxycycline, and cefuroxime axetil, the macrolides azithromycin, clarithromycin, or erythromycin may be used, although they have a lower efficacy. People treated with macrolides should be closely monitored to ensure that symptoms resolve.

Table 1.

Age Category	Drug	Dosage	Maximum	Duration, Days
Adults	Doxycycline	100 mg, twice per day orally	N/A	10-21*
	Cefuroxime axetil	500 mg, twice per day orally	N/A	14-21
	Amoxicillin	500 mg, three times per day orally	N/A	14-21
Children	Amoxicillin	50 mg/kg per day orally, divided into 3 doses	500 mg per dose	14-21
	Doxycycline	4 mg/kg per day orally, divided into 2 doses	100 mg per dose	10-21*
	Cefuroxime axetil	30 mg/kg per day orally, divided into 2 doses	500 mg per dose	14-21

*Recent publications suggest the efficacy of shorter courses of treatment for early Lyme disease.

Post-Treatment Lyme Disease Syndrome

Physicians sometimes describe patients who have non-specific symptoms (like fatigue, pain, and joint and muscle aches) after the treatment of Lyme disease as having post-treatment Lyme disease syndrome (PTLDS) or post Lyme disease syndrome (PLDS). The cause of PTLDS is not known.

The term “chronic Lyme disease” (CLD) has been used to describe people with different illnesses. While the term is sometimes used to describe illness in patients with Lyme disease, in many occasions it has been used to describe symptoms in people who have no evidence of a current or past infection with *B. burgdorferi* (Marques 2008). Because of the confusion in how the term CLD in this field is employed, experts do not support its use (Feder et al. 2007). For more information, visit the National Institutes of Health Chronic Lyme Disease site (<https://www.niaid.nih.gov/diseases-conditions/chronic-lyme-disease>).

For more information please visit:

CDC Lyme Disease Page: <https://www.cdc.gov/lyme/>

CDC Tickborne Diseases of the US: A Reference Manual for Health Care Providers, Fourth Edition (2017): <https://www.cdc.gov/lyme/resources/TickborneDiseases.pdf>

References:

Feder HM Jr, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP; Ad Hoc International Lyme Disease Group, Agger WA, Artsob H, Auwaerter P, Dumler JS, Bakken JS, Bockenstedt LK, Green J, Dattwyler RJ, Munoz J, Nadelman RB, Schwartz I, Draper T, McSweegan E, Halperin JJ, Klempner MS, Krause PJ, Mead P, Morshed M, Porwancher R, Radolf JD, Smith RP Jr, Sood S, Weinstein A, Wong SJ, Zemel L. A critical appraisal of "chronic Lyme disease". *N Engl J Med.* 2007 Oct 4; 357(14):1422-30.

Hu LT. Lyme Disease. *Ann Intern Med.* 2016 Nov 1; 165(9):677.

Marques A. Chronic Lyme disease: An appraisal. *Infect Dis Clin North Am.* 2008 Jun 1; 22(2):341-60.

Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: A review. *JAMA.* 2016 Apr 26; 315(16):1767-77.